---
title: "Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing Potential"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293521336.md"
description: "LifeSci Capital analyst Oliver McCammon reaffirmed a Buy rating on Aura Biosciences with an unchanged $23 price target. He cites bel-sar's potential to offer vision-sparing treatment for early choroidal melanoma as a key driver, contrasting it with current radiation therapies that risk vision loss. With the Phase 3 CoMpass trial fully enrolled and pivotal data expected in 2027, McCammon views the stock as having an attractive risk-reward profile."
datetime: "2026-07-22T20:55:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293521336.md)
  - [en](https://longbridge.com/en/news/293521336.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293521336.md)
generator: "portal-rs"
---

# Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing Potential

Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc, retaining the price target of $23.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Oliver McCammon has given his Buy rating due to a combination of factors, chiefly the potential of bel-sar to reshape treatment for early choroidal melanoma. His work with ocular oncology specialists highlights that current radiation-based care, while effective at local tumor control, carries a substantial and often unacceptable risk of long-term vision loss for many patients.

He views bel-sar’s targeted, light-activated mechanism as well positioned to offer a vision-sparing, outpatient alternative for small tumors and indeterminate lesions, addressing both overtreatment and delayed intervention risks identified by experts. With the Phase 3 CoMpass trial fully enrolled and pivotal data expected in 2027, alongside an unchanged $23 price target, he believes Aura Biosciences offers an attractive risk-reward profile at current levels. 

According to TipRanks, McCammon is a 5-star analyst with an average return of 78.7% and a 52.54% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Celcuity, Corbus Pharmaceuticals, and Aura Biosciences Inc.

### Related Stocks

- [AURA.US](https://longbridge.com/en/quote/AURA.US.md)
- [CELC.US](https://longbridge.com/en/quote/CELC.US.md)
- [CRBP.US](https://longbridge.com/en/quote/CRBP.US.md)

## Related News & Research

- [Aura Biosciences grants new executives stock options priced at $7.43, plus RSUs](https://longbridge.com/en/news/297695014.md)
- [Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | AURA Stock News](https://longbridge.com/en/news/297695821.md)
- [Aura Biosciences CEO to speak at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/297823184.md)
- [Bausch + Lomb study finds enVista Aspire IOLs deliver strong distance, intermediate vision in real-world use](https://longbridge.com/en/news/297773690.md)
- [HelloNation Article Examines Blue Light Glasses Featuring Optometry Expert Andrea Hill](https://longbridge.com/en/news/297711788.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**